首页> 外文期刊>Cancer immunology, immunotherapy : >Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC
【24h】

Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC

机译:肿瘤排出的淋巴结是对淋巴式肿瘤抗原的支持诱导T细胞灌注和免疫检查点阻断在TNBC中的作用

获取原文
获取原文并翻译 | 示例
           

摘要

Triple negative breast cancer (TNBC) is a significant clinical problem to which immunotherapeutic strategies have been applied with limited success. Using the syngeneic E0771 TNBC mouse model, this work explores the potential for antitumor CD8(+) T cell immunity to be primed extratumorally in lymphoid tissues and therapeutically leveraged. CD8(+) T cell viability and responses within the tumor microenvironment (TME) were found to be severely impaired, effects coincident with local immunosuppression that is recapitulated in lymphoid tissues in late stage disease. Prior to onset of a locally suppressed immune microenvironment, however, CD8(+) T cell priming within lymph nodes (LN) that depended on tumor lymphatic drainage remained intact. These results demonstrate tumor-draining LNs (TdLN) to be lymphoid tissue niches that support the survival and antigenic priming of CD8(+) T lymphocytes against lymph-draining antigen. The therapeutic effects of and CD8(+) T cells response to immune checkpoint blockade were furthermore improved when directed to LNs within the tumor-draining lymphatic basin. Therefore, TdLNs represent a unique potential tumor immunity reservoir in TNBC for which strategies may be developed to improve the effects of ICB immunotherapy.
机译:三阴性乳腺癌(TNBC)是一个重要的临床问题,免疫治疗策略的成功率有限。利用同基因E0771 TNBC小鼠模型,这项工作探索了在淋巴组织肿瘤外启动抗肿瘤CD8(+)T细胞免疫并在治疗上发挥作用的可能性。CD8(+)T细胞活性和肿瘤微环境(TME)内的反应被发现严重受损,其影响与局部免疫抑制一致,后者在晚期疾病的淋巴组织中重现。然而,在局部抑制的免疫微环境出现之前,依赖于肿瘤淋巴引流的淋巴结(LN)内的CD8(+)T细胞启动仍然完好无损。这些结果表明,肿瘤引流LN(TdLN)是淋巴组织龛,支持CD8(+)T淋巴细胞针对淋巴引流抗原的存活和抗原启动。当将CD8(+)T细胞导入肿瘤引流淋巴盆内的LNs时,其对免疫检查点阻断的反应的治疗效果进一步提高。因此,TDLN是TNBC中一个独特的潜在肿瘤免疫库,可以开发策略来提高ICB免疫治疗的效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号